BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
Public ClinicalTrials.gov record NCT01156311. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer acetate (GA) in participants with relapsing-remitting multiple sclerosis (RRMS).
Study identification
- NCT ID
- NCT01156311
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 108 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2010 (Type not available)
- Primary completion
- Mar 2012 (Actual)
- Completion
- Mar 2012 (Actual)
- Last update posted
- Mar 21, 2017
2010 – 2012
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Gilbert | Arizona | — | — |
| Research Site | Phoenix | Arizona | — | — |
| Research Site | Danbury | Connecticut | — | — |
| Research Site | Atlanta | Georgia | — | — |
| Research Site | Fort Wayne | Indiana | — | — |
| Research Site | Baltimore | Maryland | — | — |
| Research Site | Boston | Massachusetts | — | — |
| Research Site | Golden Valley | Minnesota | — | — |
| Research Site | Teaneck | New Jersey | — | — |
| Research Site | Patchogue | New York | — | — |
| Research Site | Cleveland | Ohio | — | — |
| Research Site | Dayton | Ohio | — | — |
| Research Site | Portland | Oregon | — | — |
| Research Site | Cordova | Tennessee | — | — |
| Research Site | Franklin | Tennessee | — | — |
| Research Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01156311, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 21, 2017 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01156311 live on ClinicalTrials.gov.